Press releases

Transfemoral access added into landmark APOLLO Pivotal Trial following IDE approval from FDA DUBLIN and ORLANDO, Fla., Nov. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...

TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years DUBLIN and ORLANDO, Fla., Nov. 5, 2021 /PRNewswire/ -- Medtronic plc...

New data from Medtronic Patient Preference study presented at TCT 2021; Medtronic adds to its clinical leadership for renal denervation with launch of the SPYRAL AFFIRM study DUBLIN and ORLANDO,...

Company to highlight environmental, social, and governance (ESG) efforts in inaugural ESG Investor Briefing DUBLIN, Oct. 12, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today released its fiscal...

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced a pilot program with Mpirik to address disparities in care associated with the prevention of sudden cardiac...

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the following upcoming investor conferences: 2021 Virtual Wells Fargo Healthcare...

Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021. Key Highlights Revenue of $8.0 Billion Increased 23% Reported and...

The board of directors of Medtronic plc (NYSE: MDT) on Friday, August 20, 2021, approved the fiscal year 2022 second quarter cash dividend of $0.63 per ordinary share, representing a 9 percent...

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat...

AI Algorithms Enhance LINQ II™ Insertable Cardiac Monitor Diagnostic Accuracy for Improved Management of Patients DUBLIN, July 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global...

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced new data from the landmark WRAP-IT study published in Heart Rhythm, demonstrating a significantly lower...

Economic Model Based on PRODIGY Trial Data Demonstrates Continuous Pulse Oximetry and Capnography Monitoring of High-Risk Patients May Reduce Hospital Costs by Over $500,000 Annually DUBLIN, July...

Data Were Presented at the American Diabetes Association 81st Scientific Sessions DUBLIN, June 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today...

Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2021, which ended April 30, 2021. The company reported fourth quarter worldwide revenue of $8.188...

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the following upcoming investor conferences: Jefferies Virtual Healthcare Conference

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the complete two-year outcomes from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut™...

Medtronic Launches New GSR-DEFINE Study to Expand Real-World Data to 5,000 Patients DUBLIN, May 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today...

New findings from an American College of Cardiology's (ACC) survey revealed more than half of cardiologists (57%) believe patient preparation may lead to better quality discussions around...

Minimally Invasive Option Has Potential to Provide Long-Term Management of Lung Malignancies While Protecting Lung Function DUBLIN, April 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the...

- The GI Genius™ Module Assists Physicians in Detecting Pre-Cancerous Growths; Potentially Addressing 19 Million Colonoscopies Annually - Transformative AI Colorectal Cancer Prevention Platform...

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised commercial labeling for the Intellis™...

The board of directors of Medtronic plc (NYSE: MDT) on Friday, March 5, 2021, approved the fiscal year 2021 fourth quarter cash dividend of $0.58 per ordinary share, representing a 7.4 percent...

- Q3 Revenue of $7.8 Billion Increased 0.8% as Reported and Decreased 1.0% Organically - Q3 GAAP Diluted EPS of $0.94; Q3 Non-GAAP Diluted EPS of $1.29 DUBLIN, Feb. 23, 2021 /PRNewswire/ --...

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the following upcoming investor conferences, with its executives answering...

Medtronic plc (NYSE:MDT), the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion™ thoracic stent graft system and informed physicians...